Method and system for reducing the likelihood of developing NASH in an individual diagnosed with non-alcoholic fatty liver disease
View Patent ↗A method for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease that involves providing an individual with an effective amount of a composition of bacteria modified using a Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-associated system (CRISPR-Cas) or Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (CRISPR/Cpf1) system so that the bacteria is able to produce a therapeutically effective amount of anti-bodies to oxidized low density lipoprotein, with the modified bacteria preferably being from the Lactobacillus, Bifidobacterium , and Streptococcus species; and most preferably including L. reuteri bacteria modified using CRISPR-Cas and/or Cpf1 systems so that it is able to survive the conditions in the duodenum and jejunum of the small intestine of a human.
1. A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease, comprising: providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species; administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and inhibiting monoacylglycerolacyltransferase-3 (MGAT3) synthesis in the individual to lower triacylglycerol (TAG) production.
2. The method as set forth in claim 1 , wherein the beneficial bacteria are present on a thin film mucosal layered strip, said beneficial bacteria being encapsulated in a frangible enclosure.
3. The method as set forth in claim 1 , further comprising inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual.
4. The method as set forth in claim 1 , further comprising increasing the levels of Roseburia , while reducing the levels of Akkermansia spp. in the individual's gut microbiome.
5. The method as set forth in claim 4 , wherein the population of beneficial bacteria include bacteria that have been modified to increase the level of butyrate.
6. A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease, comprising: providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species; administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual.
7. The method as set forth in claim 6 , further comprising increasing the levels of Roseburia , while reducing the levels of Akkermansia spp. in the individual's gut microbiome.
8. The method as set forth in claim 6 , wherein the beneficial bacteria are present on a thin film mucosal layered strip, said beneficial bacteria being encapsulated in a frangible enclosure.
9. The method as set forth in claim 6 , wherein the population of beneficial bacteria include bacteria that have been modified to increase the level of butyrate.
10. A method for reducing the likelihood of developing non-alcoholic steatohepatitis (NASH) in an individual diagnosed with non-alcoholic fatty liver disease, comprising: providing in the gut of an individual a population of beneficial bacteria selected from the group consisting of Lactobacillus species; administering at least 6 grams per day of fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual; and increasing the levels of Roseburia , while reducing the levels of Akkermansia spp. in the individual's gut microbiome.
11. The method as set forth in claim 10 , further comprising inhibiting expression of diacylglycerolacyltransferase-2 (DGAT-2) in said individual.
12. The method as set forth in claim 10 , wherein the beneficial bacteria are present on a thin film mucosal layered strip, said beneficial bacteria being encapsulated in a frangible enclosure.
13. The method as set forth in claim 10 , wherein the population of beneficial bacteria include bacteria that have been modified to increase the level of butyrate.